Format

Send to

Choose Destination
Clin Cancer Res. 2014 Dec 1;20(23):6006-15. doi: 10.1158/1078-0432.CCR-14-1415. Epub 2014 Oct 7.

Predicting breast tumor response to neoadjuvant chemotherapy with diffuse optical spectroscopic tomography prior to treatment.

Author information

1
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire. shudong.jiang@dartmouth.edu.
2
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire.
3
Department of Medicine, Giesel School of Medicine, Hanover, New Hampshire.
4
Department of Community and Family Medicine, Giesel School of Medicine, Hanover, New Hampshire.
5
Department of Diagnostic Radiology, Giesel School of Medicine, Hanover, New Hampshire.
6
Department of Pathology, Giesel School of Medicine, Hanover, New Hampshire.
7
Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire. Department of Diagnostic Radiology, Giesel School of Medicine, Hanover, New Hampshire.

Abstract

PURPOSE:

To determine whether pretreatment biomarkers obtained from diffuse optical spectroscopic tomographic (DOST) imaging predicts breast tumor response to neoadjuvant chemotherapy (NAC), which would have value to potentially eliminate delays in prescribing definitive local regional therapy that may occur from a standard complete 6- to 8-month course of NAC.

EXPERIMENTAL DESIGN:

Nineteen patients undergoing NAC were imaged with DOST before, during, and after treatment. The DOST images of total hemoglobin concentration (HbT), tissue oxygen saturation (StO2), and water (H2O) fraction at different time points have been used for testing the abilities of differentiating patients having pathologic complete response (pCR) versus pathologic incomplete response (pIR).

RESULTS:

Significant differences (P < 0.001, AUC = 1.0) were found between pCR patients versus pIR in outcome, based on the percentage change in tumor HbT within the first cycle of treatment. In addition, pretreatment tumor HbT (pretreatment HbT) relative to the contralateral breast was statistically significant (P = 0.01, AUC = 0.92) in differentiating pCR from pIR.

CONCLUSIONS:

This is the first clinical evidence that DOST HbT may differentiate the two groups with predictive significance based on data acquired before NAC even begins. The study also demonstrates the potential of accelerating the validation of optimal NAC regimens through future randomized clinical trials by reducing the number of patients required and the length of time they need to be followed by using a validated imaging surrogate as an outcome measure.

PMID:
25294916
PMCID:
PMC4254218
DOI:
10.1158/1078-0432.CCR-14-1415
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center